How Generative AI Enables Medical Image Segmentation in Ultra Low-Data Regimes
Explore the potential of generative AI segmentation and its transformative impacts on data analysis and marketing strategies.
Explore the potential of generative AI segmentation and its transformative impacts on data analysis and marketing strategies.
Neuroimaging techniques in drug side effects reveal how medications alter brain function, structure, and chemistry over time.
Understand the benefits of early disease detection and its impact on public health through advanced medical imaging.
Yttrium-90 Edotreotide delivers targeted beta radiation therapy to somatostatin receptor-positive neuroendocrine tumours with precision.
Yttrium-90 DOTALAN delivers targeted beta radiation to somatostatin receptor-expressing tumours, treating neuroendocrine neoplasms effectively.
Rhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
Lead-212 VMT-α-NET offers advanced targeted therapy for neuroendocrine tumours by harnessing precise alpha-particle radiation.
Lead-212 DOTAMTATE targets somatostatin receptors in neuroendocrine tumours, delivering potent alpha-emission therapy with minimal off-target toxicity.
Lutetium-177 Satoreotide Tetratexan is a radiopharmaceutical targeting somatostatin receptors, providing advanced therapeutic options for neuroendocrine neoplasms effectively.
Lutetium-177 Oxodotreotide Treatment offers targeted neuroendocrine tumour therapy, improving progression-free survival and patient outcomes significantly.
Lutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
Lutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
Lutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
Lutetium-177 DTPA-Omburtamab offers hope in neuroblastoma treatment by precisely targeting B7-H3, delivering localised radiation while sparing healthy tissues.
The study critically evaluates 3D-to-2D knowledge distillation in neuroimaging classification, balancing volumetric insights with computational efficiency for real-world applications.
Iodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 Iobenguane revolutionises neuroendocrine tumour management by offering targeted imaging and therapy, significantly improving diagnosis, treatment, and patient outcomes.
Peptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
The REAL-LU study highlights Lutetium-177 DOTATATE’s real-world effectiveness, safety, and quality-of-life impact in Italian patients with GEP-NETs.